Question · Q3 2025
JP inquired about the payer guidelines engagement strategy for fast-acting meloxicam, specifically targeting multimodal pain pathways or traditional retail channels. He also asked about the commercialization approach for presbyopia medicine, questioning if it would initially be cash-pay or if broader reimbursement is anticipated.
Answer
Chief R&D Officer Philippe Martin stated that for meloxicam, Viatris expects to leverage the market trend towards a multimodal approach in acute pain. CFO Doretta Mistras explained that for presbyopia, Viatris is still developing the commercialization strategy as part of a broader eye care portfolio, naturally assuming a large cash-pay component initially. CEO Scott Smith added that Viatris is pleased with progress in eye care, building a portfolio of assets.